FDA Grants Orphan Drug Status To Eisai's Investigational Compound (E7777) For Cutaneous T-Cell Lymphoma
WOODCLIFF LAKE, N.J., Aug. 8, 2013 -- (Healthcare Sales & Marketing Network) -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational compound (E7777) for cutaneous t-cell ly... Biopharmaceuticals, Oncology, FDAEisai, orphan drug, E7777, cutaneous t-cell lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 8, 2013 Category: Pharmaceuticals Source Type: news
Skin Infections With Electron Beam Therapy for Mycosis...Skin Infections With Electron Beam Therapy for Mycosis...
There is a significant risk of cutaneous infection during total skin electron beam therapy (TSEBT) for mycosis fungoides, according to a new case series. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 26, 2013 Category: Consumer Health News Tags: Dermatology News Source Type: news
Non-mycosis Fungoides Cutaneous T-cell LymphomasNon-mycosis Fungoides Cutaneous T-cell Lymphomas
Primary cutaneous CD30+ T-cell lymphoproliferative disorders and their differential diagnosis are highlighted in this report from the European Society for Hematopathology. American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 19, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Anti-Cancer Drug Reverses Alzheimer's Disease In Mice
An anti-cancer drug may reverse memory problems in an Alzheimer's Disease mouse model, according to new research carried out at the University of Pittsburgh Graduate School of Public Health. The study, published in the journal Science, examined previously published outcomes on the drug bexarotene - which is approved by the U.S. Food and Drug Administration for use in cutaneous T cell lymphoma... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 25, 2013 Category: Consumer Health News Tags: Alzheimer's / Dementia Source Type: news
Mycosis Fungoides and Sézary Syndrome
The development of array comparative genomic hybridization (aCGH) techniques has allowed to characterize more precisely several human neoplasms with the aim of providing prognostic markers and targets for directed therapeutic intervention. Recently, several studies applying aCGH technique have been reported in which an exhaustive genetic characterization of mycosis fungoides (MF) and Sézary syndrome (SS) has been performed. Regarding MF, a genomic profile characterized by the gains of 7q, 17q, and 8q and losses in 9p, 13q, 17p, and 10q has been described. In SS, the most common abnormalities are gains in 8q and 17q ...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news
Array-CGH Analysis of Cutaneous Anaplastic Large Cell Lymphoma
This chapter describes a study in which the pattern of numerical chromosomal alterations in cutaneous anaplastic large cell lymphoma (C-ALCL) tumor samples was defined using array-based comparative genomic hybridization (CGH). First, the array-based CGH technique applied is outlined in detail. Next, its application in the analysis of C-ALCL tumor specimens is described. This approach resulted in the identification of highly recurrent chromosomal alterations in C-ALCL that include gain of 7q31 and loss on 6q16-6q21 and 13q34, each affecting 45% of the patients. The pattern characteristic of C-ALCL differs markedly from chro...
Source: Springer protocols feed by Genetics/Genomics - February 15, 2013 Category: Genetics & Stem Cells Source Type: news
Classification of Mycosis Fungoides and Sezary SyndromeClassification of Mycosis Fungoides and Sezary Syndrome
This article focuses on the evaluation and classification of mycosis fungoides and Sezary syndrome, two of the most common forms of cutaneous t-cell lymphoma. What treatment options are available? Skin Therapy Letter (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 4, 2013 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
A Leukemia Drug Kills Cancerous T-cells While Sparing Normal Immunity
Campath not only treats patients with L-CTCL but does so without increasing their risk of infections. (Source: BWH News)
Source: BWH News - January 25, 2012 Category: Hospital Management Source Type: news
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options
Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra™, GlaxoSmithKline) as a therapy option for patients with chronic lymphocytic leukemia (CLL) and romidepsin (Istodax®, Gloucester Pharmaceuticals) as a suggested treatment for patients with cutaneous T-cell lymphoma (CTCL).
November 23, 2009
FORT WASHINGTON, PA - Two recent FDA approvals have prompted the National Comprehensive Cance... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - November 23, 2009 Category: Cancer & Oncology Source Type: news
Combination Cancer Therapy is Focus of $1M Merck Research Grant Received by NCCN
NCCN has been awarded a $1M research grant from Merck & Co, Inc., that will support research of the anti-cancer agent vorinostat (Zolinza®). Vorinostat is currently used to treat progressive, persistent, or recurrent cutaneous T-cell lymphoma. This research grant will fund studies to explore the efficacy of vorinostat in combination with chemotherapy and/or radiation therapy in selected locally advanced non-metastatic cancers including non-small cell lung cancer, head and neck cancer, panc... (Source: National Comprehensive Cancer Network Oncology Research Program)
Source: National Comprehensive Cancer Network Oncology Research Program - December 1, 2008 Category: Cancer & Oncology Source Type: news
